Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Fishbane

Showing results (111-120 of 234) with videos related to

Pageof 24
Sort By:
Kidney International|October 15, 2015
Reducing hospital readmissions in patients with end-stage kidney diseaseAnna T Mathew, Giovanni F M Strippoli, Marinella Ruospo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 28, 2012
Subgroup analyses in nephrology clinical trialsSteven Fishbane, Hitesh H Shah, Ashish Kataria, et al.
Kidney International Reports|December 13, 2021
Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe HyperkalemiaMartin Ford, Steven Fishbane, Bruce Spinowitz, et al.
Nature Clinical Practice. Nephrology|August 26, 2006
Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complexBeckie Michael, Steven Fishbane, Daniel W Coyne, et al.
International Journal of Nephrology|May 9, 2022
Course of Hyperkalemia in Patients on HemodialysisBruce Spinowitz, Steven Fishbane, Masafumi Fukagawa, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 15, 2024
Challenges and Opportunities in Advanced Chronic Kidney DiseaseSteven Fishbane, Candice Halinski, Alla Alaiev, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 21, 2018
Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney DiseaseSteven Fishbane, Bhupinder Singh, Seema Kumbhat, et al.
Kidney International Reports|January 11, 2018
Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative ReviewKenar D Jhaveri, Rimda Wanchoo, Vipulbhai Sakhiya, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 15, 2009
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trialSteven Fishbane, Harini Chittineni, Michal Packman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 3, 2015
Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and AnemiaDavid M Charytan, Steven Fishbane, Jolanta Malyszko, et al.
Pageof 24

Showing results (111-120 of 234) with videos related to

Sort By:
Pageof 24
Kidney International|October 15, 2015
Reducing hospital readmissions in patients with end-stage kidney diseaseAnna T Mathew, Giovanni F M Strippoli, Marinella Ruospo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 28, 2012
Subgroup analyses in nephrology clinical trialsSteven Fishbane, Hitesh H Shah, Ashish Kataria, et al.
Kidney International Reports|December 13, 2021
Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe HyperkalemiaMartin Ford, Steven Fishbane, Bruce Spinowitz, et al.
Nature Clinical Practice. Nephrology|August 26, 2006
Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complexBeckie Michael, Steven Fishbane, Daniel W Coyne, et al.
International Journal of Nephrology|May 9, 2022
Course of Hyperkalemia in Patients on HemodialysisBruce Spinowitz, Steven Fishbane, Masafumi Fukagawa, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 15, 2024
Challenges and Opportunities in Advanced Chronic Kidney DiseaseSteven Fishbane, Candice Halinski, Alla Alaiev, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 21, 2018
Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney DiseaseSteven Fishbane, Bhupinder Singh, Seema Kumbhat, et al.
Kidney International Reports|January 11, 2018
Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative ReviewKenar D Jhaveri, Rimda Wanchoo, Vipulbhai Sakhiya, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 15, 2009
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trialSteven Fishbane, Harini Chittineni, Michal Packman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 3, 2015
Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and AnemiaDavid M Charytan, Steven Fishbane, Jolanta Malyszko, et al.
Pageof 24